Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer

Androgen receptor (AR) is widely expressed in different subtypes of breast cancer (BC). However, it is unclear how AR functions in HER2 positive (+) BC. Knockdown of AR with shRNAs and a new generation anti-androgen drug, Enzalutamide, were used to explore the involvement of AR on the growth of HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Licai, Du, Zhuanyun, Xiong, Xusheng, Ma, Hua, Zhu, Zhenfeng, Gao, Hongwei, Cao, Jiawei, Li, Tong, Li, Hongzhi, Yang, Kaiyan, Chen, Guorong, Richer, Jennifer K., Gu, Haihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674043/
https://www.ncbi.nlm.nih.gov/pubmed/29109513
http://dx.doi.org/10.1038/s41598-017-14607-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674043/
https://www.ncbi.nlm.nih.gov/pubmed/29109513
http://dx.doi.org/10.1038/s41598-017-14607-2

Ejemplares similares